Literature DB >> 21613802

Aberrant expression of disintegrin-metalloprotease proteins in the formation and progression of uterine cervical cancer.

Mohammed Shaker1, Yuhki Yokoyama, Seiji Mori, Masahiko Tsujimoto, Naomasa Kawaguchi, Tohru Kiyono, Toru Nakano, Nariaki Matsuura.   

Abstract

OBJECTIVE: Dysregulated expression of disintegrin-metalloprotease proteins [a disintegrin and metalloproteases (ADAMs) and ADAMs with thrombospondin motif (ADAMTSs)] has been reported in many types of cancers and is believed to play an important role in cancer formation and metastasis. However, little is known about the expression of ADAMs and ADAMTSs in the development of human cervical cancer.
METHODS: Reverse transcriptase polymerase chain reaction and immunoblotting were performed to assess the expression of several disintegrin-metalloproteases and tissue inhibitors of metalloproteinases (TIMPs) in squamous-type cervical cancer cells and oncogenically modified keratinocytes (immortalized human cervical keratinocytes transduced with human papilloma virus-16 E6/E7 proteins with or without oncogenes). Immunohistochemistry of ADAM-9, ADAM-10 and TIMP-3 was performed on 31 primary human cervical tissue specimens of preinvasive and invasive cervical carcinoma.
RESULTS: mRNA levels of ADAM-9, ADAM-10, ADAM-12, TIMP-2 and TIMP-3 were upregulated as cervical cells progressed from dysplastic to malignant lesions compared to normal cervical cells. These results were corroborated at the protein level by Western blot analysis and immunohistochemistry.
CONCLUSION: The expression of disintegrin-metalloproteases and their endogenous regulators was dysregulated during cervical carcinogenesis. The aberrant expression of ADAMs might contribute to the pathogenesis of cervical cancer formation and progression.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21613802     DOI: 10.1159/000324314

Source DB:  PubMed          Journal:  Pathobiology        ISSN: 1015-2008            Impact factor:   4.342


  3 in total

1.  Overexpression of ADAM9 in oral squamous cell carcinoma.

Authors:  Pattaramon Tanasubsinn; Win Pa Pa Aung; Supansa Pata; Witida Laopajon; Anupong Makeudom; Thanapat Sastraruji; Watchara Kasinrerk; Suttichai Krisanaprakornkit
Journal:  Oncol Lett       Date:  2017-10-30       Impact factor: 2.967

2.  Expression of ADAM10, Fas, FasL and Soluble FasL in Patients with Oral Squamous Cell Carcinoma (OSCC) and their Association with Clinical-Pathological Parameters.

Authors:  José Sergio Zepeda-Nuño; Celia Guerrero-Velázquez; Susana Del Toro-Arreola; Natali Vega-Magaña; Julián Ángeles-Sánchez; Jesse Haramati; Ana L Pereira-Suárez; Miriam R Bueno-Topete
Journal:  Pathol Oncol Res       Date:  2016-09-14       Impact factor: 3.201

3.  Loss of histone H4K20 trimethylation predicts poor prognosis in breast cancer and is associated with invasive activity.

Authors:  Yuhki Yokoyama; Ayaka Matsumoto; Miki Hieda; Yoshimi Shinchi; Eri Ogihara; Mai Hamada; Yu Nishioka; Hiroshi Kimura; Katsuhide Yoshidome; Masahiko Tsujimoto; Nariaki Matsuura
Journal:  Breast Cancer Res       Date:  2014-06-22       Impact factor: 6.466

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.